Your browser doesn't support javascript.
Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2.
Wines, Bruce D; Kurtovic, Liriye; Trist, Halina M; Esparon, Sandra; Lopez, Ester; Chappin, Klasina; Chan, Li-Jin; Mordant, Francesca L; Lee, Wen Shi; Gherardin, Nicholas A; Patel, Sheila K; Hartley, Gemma E; Pymm, Phillip; Cooney, James P; Beeson, James G; Godfrey, Dale I; Burrell, Louise M; van Zelm, Menno C; Wheatley, Adam K; Chung, Amy W; Tham, Wai-Hong; Subbarao, Kanta; Kent, Stephen J; Hogarth, P Mark.
  • Wines BD; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Kurtovic L; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.
  • Trist HM; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Esparon S; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, Australia.
  • Lopez E; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.
  • Chappin K; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Chan LJ; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Mordant FL; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Lee WS; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Gherardin NA; Immune therapies Laboratory, Burnet Institute, Melbourne, VIC, Australia.
  • Patel SK; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Hartley GE; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Pymm P; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Cooney JP; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Beeson JG; Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
  • Godfrey DI; Department of Medicine, Austin Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Burrell LM; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • van Zelm MC; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Wheatley AK; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Chung AW; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
  • Tham WH; Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia.
  • Subbarao K; Life Sciences, Burnet Institute, Melbourne, VIC, Australia.
  • Kent SJ; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Hogarth PM; Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia.
Front Immunol ; 13: 1122516, 2022.
Article in English | MEDLINE | ID: covidwho-2246352
ABSTRACT
[This corrects the article .].
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1122516

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.1122516